December 31, 2013 | Hadasit Bio-Holdings, the commercialization branch of Hadassah Medical Center, has received NIS 25 million (approx. $7.2 million) from the Office of the Chief Scientist. The funds will be directed towards three of Hadasit’s portfolio companies: Cell Cure, KAHR Medical and Enlivex Therapeutics.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments